the public record, side by side

Celexa (citalopram) vs Lexapro (escitalopram)

Celexa and Lexapro, compared on what the public record actually supports: side effects by rate from each FDA label, what the largest trial comparison found, who takes each one, who pays, what the labels warn, and what the litigation record holds. Sources on every number.

the short answer

is Celexa or Lexapro more effective? in the largest comparison of antidepressant trials (522 trials, 116,477 people, Lancet 2018), both beat placebo on response at about 8 weeks: citalopram odds ratio 1.52 (95% CrI 1.33 to 1.74), escitalopram 1.68 (1.50 to 1.87). the authors called the differences between drugs mostly modest, with wide intervals. the two Cochrane reviews that pooled the direct trials both found escitalopram ahead of citalopram on response at about 8 weeks (odds ratio 1.47, 95% CI 1.08 to 2.02 in the 2012 citalopram review), with a sponsorship-bias warning attached; the one everyday difference in the labels is that citalopram carries a 40 mg daily cap for QT prolongation and escitalopram does not.
which has fewer side effects? the labels say their trials “cannot be directly compared”, because each drug was tested in different people under different rules. what each label prints: Celexa (citalopram): 16% stopped for an adverse reaction vs 8% on placebo (Celexa label, Revised: 10/2023). Lexapro (escitalopram): 6% stopped for an adverse reaction vs 2% on placebo (Lexapro label, Revised:4/2024 (as printed in the SPL)). the reactions both labels list, side by side, are in the table below. in the 2018 network, all-cause dropout against placebo was 0.94 for citalopram and 0.90 for escitalopram.
which should i take? not a question this page answers. the odds ratios are averages across thousands of strangers; your history, other medications and what you can live with are not in them. the questions for your prescriber below are built from what is on this page.

What this page will not do is rank them. For most same-class pairs, head-to-head efficacy differences are smaller than the rankings look — the largest network meta-analysis ever run (21 antidepressants, 522 trials) found every drug beat placebo and the gaps between drugs mostly modest and uncertain. Which one fits you turns on your history, your other medications, and side-effect trade-offs — a prescriber conversation. This page arms that conversation; here are the questions worth taking into it →

what the 522-trial comparison found for citalopram and escitalopram

the 2018 Lancet network meta-analysis pooled 522 trials comprising 116 477 participants, the median duration of the acute treatment was 8 weeks (iqr 6–8), and compared 21 antidepressants against placebo and against each other on two outcomes: response (at least a 50% fall on the depression scale) and all-cause dropout, its stand-in for acceptability. odds ratios are against placebo. an odds ratio above 1 on response favours the drug; below 1 on dropout means fewer people stopped than on placebo.

drug	response vs placebo, OR (95% CrI)	dropout vs placebo, OR (95% CrI)
Celexa (citalopram)	1.52 (1.33 to 1.74)	0.94 (0.80 to 1.09)
Lexapro (escitalopram)	1.68 (1.50 to 1.87)	0.90 (0.80 to 1.02)

citalopram: among the more tolerable (fewer dropouts) in head-to-head trials.
escitalopram: among the drugs that were more effective than other antidepressants in head-to-head trials; among the more tolerable (fewer dropouts) in head-to-head trials.

the other direction, in the authors' words. “the certainty of evidence was moderate to very low”; “The random-effects summary SMD for all antidepressants was 0·30 (95% CrI 0·26–0·34)”, a modest average effect; “positive results need to be taken with great caution, because the trials in this network meta-analysis were of short duration”. 46 (9%) of 522 trials were rated as high risk of bias, 380 (73%) trials as moderate, and 96 (18%) as low. 409 (78%) of 522 studies were funded by pharmaceutical companies. the trials excluded people with psychotic, treatment-resistant or bipolar depression, and the paper says it cannot guide the next choice after a first drug fails. a difference between two odds ratios in the table above is not a difference between the drugs unless the direct comparison shows one.

Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; doi:10.1016/S0140-6736(17)32802-7. funding of the analysis: National Institute for Health Research Oxford Health Biomedical Research Centre and the Japan Society for the Promotion of Science. The funder of this study had no role in study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit for publication. read 2026-10-11 at PMC.

the trials that compared these two directly, and the dose cap that separates their labels

who paid: the two Cochrane reviews quoted here are academic (University of Verona and collaborators). the direct trials they pool were run on fixed doses the trial sponsors chose, and both drugs come from the same developer, which is why the Cochrane authors write that "the potential for overestimation of treatment effect due to sponsorship bias should also be borne in mind." that caveat applies to every escitalopram-beats-citalopram number below.

the 2009 Cochrane review of escitalopram (searched to July 2008; 14 trials against other SSRIs) found escitalopram "significantly more effective than citalopram in achieving acute response (OR 0.67, 95% CI 0.50 to 0.87)" and remission (OR 0.53, 0.30 to 0.93), odds ratios written so that below 1 favours escitalopram. it found "insufficient evidence to detect a difference" in early response at two weeks.
the 2012 Cochrane review of citalopram (searched to February 2012; 37 trials) reports the same comparison from the other side: citalopram "significantly less effective than escitalopram in achieving acute response (odds ratio (OR) 1.47, 95% confidence interval (CI) 1.08 to 2.02)". in the other direction, citalopram was more effective than paroxetine (OR 0.65, 0.44 to 0.96) and reboxetine, and fewer people on citalopram reported a side effect than on reboxetine or venlafaxine. (Cipriani A, Purgato M, Furukawa TA, et al. Cochrane 2012; doi 10.1002/14651858.CD006534.pub2.)
the direct trials behind those pooled numbers, at the doses that were actually compared: escitalopram 20 mg against citalopram 40 mg over 8 weeks (Moore 2005, 280 evaluable outpatients with MADRS 30 or more): responders 76.1% vs 61.3%, remission 56.1% vs 43.6%, "tolerability was similar". escitalopram 10 mg against citalopram 20 mg over 24 weeks in primary care (Colonna 2005, 357 patients): "at least as efficacious" on the primary measure, better on the clinician severity scale at week 24, fewer withdrawals after week 8, "overall adverse event profiles for the two drugs were similar". escitalopram 10 mg against citalopram 10 mg and 20 mg over 6 weeks (Yevtushenko 2007, 322 outpatients in Russia): response 95.4% vs 44.3% and 83.3%, remission 89.8% vs 25.5% and 50.9%, rates far above anything the other trials of either drug report.
the two placebo-controlled trials that used citalopram as the reference (Lepola 2003, 469 primary-care patients; pooled with a second study in Lepola 2004) found both drugs beat placebo; escitalopram separated from placebo at week 1 and citalopram at week 6, and adverse-event withdrawal was at placebo level for both (3% and 4%).
the dose cap, from the labels read on 2026-10-20 (Celexa label set 4259d9b1, version 40; Lexapro label set 13bb8267, version 45): the citalopram label says "Dosages above 40 mg once daily are not recommended due to the risk of QT prolongation", limits patients over 60, patients with hepatic impairment and CYP2C19 poor metabolizers to 20 mg a day, says to avoid the drug in congenital long QT syndrome, bradycardia, low potassium or magnesium, recent heart attack or uncompensated heart failure, and to stop it if QTc stays above 500 ms. the escitalopram label caps the dose at 20 mg ("No additional benefits were seen at 20 mg once daily") and its warnings section carries no QT item at all; QT prolongation appears only in its post-marketing list and its pharmacology section.
the numbers behind the cap, from FDA’s 28 March 2012 safety communication (which revised its August 2011 notice): in the same kind of thorough QT study, the mean QTc change was 8.5 ms at citalopram 20 mg, 12.6 ms at 40 mg (estimated) and 18.5 ms at 60 mg, against 4.5 ms at escitalopram 10 mg, 6.6 ms at 20 mg (estimated) and 10.7 ms at 30 mg. the positive control (moxifloxacin 400 mg) produced 13.4 ms in the citalopram study and 9.0 ms in the escitalopram study, so the top dose of each drug exceeded its own study’s control; only citalopram’s did so at 1.5 times its maximum recommended dose. the notice’s own words: "Citalopram is not recommended for use at doses greater than 40 mg per day because such doses cause too large an effect on the QT interval and confer no additional benefit."

limits: every direct trial compared fixed doses, so "escitalopram beat citalopram" always means "at these doses", and 10 mg of the single enantiomer is not the same amount of active drug as 20 mg of the racemate. the Cochrane authors flag sponsorship bias; the two reviews are from 2009 and 2012; the 2018 Lancet network above, which pooled far more trials, gives both drugs overlapping intervals against placebo (escitalopram 1.68, 1.50 to 1.87; citalopram 1.52, 1.33 to 1.74) and names escitalopram among the more effective and both among the more tolerable drugs in its head-to-head analysis. the QT cap is about doses above 40 mg and about specific groups; it is not a finding about an everyday 20 mg dose. none of this is a verdict about you.

Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2009; doi: 10.1002/14651858.CD006532.pub2. read 2026-10-20.

side effects by rate: what each label prints, not a head-to-head trial

the labels' own warning, first: “Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.” the two columns below come from different trials, in different people, under different inclusion rules. read each against its own placebo column, not against the other drug.

reaction	CELEXA (N=1,063) vs Placebo (N=446)	Lexapro (N=715) vs Placebo (N=592)
nausea	21% vs 14%	15% vs 7%
dry mouth	20% vs 14%	6% vs 5%
diarrhea	8% vs 5%	8% vs 5%
insomnia	15% vs 14%	9% vs 4%
somnolence	18% vs 10%	6% vs 2%
fatigue	5% vs 3%	5% vs 2%
sweating	11% vs 9%	5% vs 2%
decreased appetite	4% vs 2%	3% vs 1%
libido decreased	2% vs <1%	3% vs 1%
ejaculation disorder	6% vs 1%	9% vs <1%
erectile dysfunction	3% vs <1%	3% vs <1%

Celexa (citalopram): 16% stopped for an adverse reaction vs 8% on placebo (Celexa label, Revised: 10/2023).
Lexapro (escitalopram): 6% stopped for an adverse reaction vs 2% on placebo (Lexapro label, Revised:4/2024 (as printed in the SPL)).

what makes each table, in the labels' words

Celexa (citalopram), Revised: 10/2023, 6 ADVERSE REACTIONS / 6.1 Clinical Trials Experience. inclusion rule: “Adverse reactions reported by at least 2% of patients treated with CELEXA are reported, except for the following adverse reactions which had an incidence on placebo ≥ CELEXA: headache, asthenia, dizziness, constipation, palpitation, vision abnormal, sleep disorder, nervousness, pharyngitis, micturition disorder, back pain.” trials: “Table 3 enumerates the incidence of adverse reactions that occurred among 1,063 patients with MDD who received CELEXA at doses ranging from 10 mg to 80 mg once daily in placebo-controlled trials of up to 6 weeks duration.” DailyMed
Lexapro (escitalopram), Revised:4/2024 (as printed in the SPL), 6 ADVERSE REACTIONS / 6.1 Clinical Trials Experience. inclusion rule: “Reactions included are those occurring in 2% or more of patients treated with Lexapro and for which the incidence in patients treated with Lexapro was greater than the incidence in placebo-treated patients.” trials: “Adverse reactions information for Lexapro was collected from 715 patients with major depressive disorder who were exposed to escitalopram and from 592 patients who were exposed to placebo in double-blind, placebo-controlled trials. Doses ranged from 10 to 20 mg/day; incidences are rounded to the nearest percent by the label itself.” DailyMed

every row above was transcribed from the current FDA label on 2026-09-08; the full tables, including the reactions only one label lists, are on side-effect rates, drug vs placebo. the sexual side-effect rows carry each label's own underreporting caveat on the SSRI sexual side effects page.

citalopram (Celexa)

SSRI antidepressant

FDA approval: 1998 · full approval journey →
Who takes it (US, 2024): 2,876,646 patients · 12,504,000 prescriptions (AHRQ MEPS)2014 → 2024: 29,737,922 → 12,504,000 prescriptions, down 58%Correction (29 September 2026): An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves. It showed 2,876,645 people and 12,500,214 prescriptions for 2024; the file gives 2,876,646 and 12,504,000.
Who pays (2024): Medicare: 6,743,311 claims · 1,422,360 beneficiariesMedicaid: ≥2,096,752 prescriptionsCommercial claims: not published in any public dataset — a real absence, not a zero.
Boxed warning: Yes — on the current FDA label. read it in context →
Adverse-event reports (FAERS): Caveat first: FAERS counts unverified REPORTS, not patients or rates — no denominator, and attention inflates reporting. Never compare these counts head-to-head; a longer-marketed, more-prescribed drug accumulates more reports by exposure alone. how to read FAERS →106,559 all-time reports; most-reported terms: fatigue, nausea, drug ineffective
Legal & safety record: the full litigation & recall record →

escitalopram (Lexapro)

SSRI antidepressant

FDA approval: 2002 · full approval journey →
Who takes it (US, 2024): 9,460,411 patients · 41,800,787 prescriptions (AHRQ MEPS)2014 → 2024: 19,639,202 → 41,800,787 prescriptions, up 113%Correction (29 September 2026): An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves. It showed 9,451,175 people and 41,773,078 prescriptions for 2024; the file gives 9,460,411 and 41,800,787.
Who pays (2024): Medicare: 12,700,559 claims · 2,728,707 beneficiariesMedicaid: ≥6,618,277 prescriptionsCommercial claims: not published in any public dataset — a real absence, not a zero.
Boxed warning: Yes — on the current FDA label. read it in context →
Adverse-event reports (FAERS): Caveat first: FAERS counts unverified REPORTS, not patients or rates — no denominator, and attention inflates reporting. Never compare these counts head-to-head; a longer-marketed, more-prescribed drug accumulates more reports by exposure alone. how to read FAERS →139,512 all-time reports; most-reported terms: fatigue, nausea, drug ineffective
Legal & safety record: the full litigation & recall record →

questions for your prescriber, built from this page

this page does not tell you to start, stop or switch anything. it arms the conversation where that decision belongs. take these in:

which of Celexa and Lexapro did you have in mind first, and what in my history points that way?
the trials put these two close together on average. what, for me specifically, breaks the tie: another medication i take, a side effect i can't live with, sleep, weight, sexual function?
the label lists these reactions above placebo for the one you're suggesting. which of them should i expect in the first weeks, and which would make you want to hear from me the same day?
how long were the approval trials, and what do we know past that point?
how will we judge whether it is working, by when, and what is the plan if it isn't?
if i ever want to come off it, how is that done, and over how long?
is there a cheaper generic or a formulation that changes the dosing, and does my insurance prefer one of these two?

the longer checklist, for any antidepressant, is questions to ask before starting antidepressants. if you are already on one and it feels like it stopped working, that has its own page.

What the warnings mean, drug by drug

Each explainer reads one drug's current FDA label and the studies in our library, in both directions: the boxed warnings with the label's own numbers, the trials behind the approval and how long they ran, side effects by rate, and the research since.

Questions people search

Is Celexa or Lexapro better?

No honest page can answer that in one line. Head-to-head differences between comparable psychiatric medications are usually smaller than rankings suggest, and which fits you depends on your history, other medications, and side-effect trade-offs, a prescriber conversation. What can be compared is the public record (usage, payers, label warnings, approval history, litigation), which is what this page does, with sources.

Is Celexa the same as citalopram, and Lexapro the same as escitalopram?

Celexa is a brand name for citalopram. Lexapro is a brand name for escitalopram. citalopram is a SSRI antidepressant; escitalopram is a SSRI antidepressant. This page uses the generic names because the federal datasets do.

Which has fewer side effects, Celexa or Lexapro?

The two FDA labels cannot be compared head to head, in their own words, because each drug's trials ran in different people under different rules. What each label prints: Celexa (citalopram): 16% stopped for an adverse reaction vs 8% on placebo (Celexa label, Revised: 10/2023). Lexapro (escitalopram): 6% stopped for an adverse reaction vs 2% on placebo (Lexapro label, Revised:4/2024 (as printed in the SPL)). The page shows the reactions both labels list, each against its own placebo column. In the 2018 Lancet network meta-analysis, all-cause dropout against placebo was 0.94 for citalopram and 0.90 for escitalopram.

Is Celexa or Lexapro more effective for depression?

In the 2018 Lancet network meta-analysis of 522 trials and 116,477 adults with major depressive disorder, both beat placebo on response at about 8 weeks: citalopram odds ratio 1.52 (95% CrI 1.33 to 1.74), escitalopram 1.68 (1.50 to 1.87). The authors described the differences between drugs as mostly modest, with wide intervals. The two Cochrane reviews that pooled the direct trials both found escitalopram ahead of citalopram on response at about 8 weeks (odds ratio 1.47, 95% CI 1.08 to 2.02 in the 2012 citalopram review), with a sponsorship-bias warning attached; the one everyday difference in the labels is that citalopram carries a 40 mg daily cap for QT prolongation and escitalopram does not. The certainty of evidence was moderate to very low, 78% of the trials were industry funded, and the pooled effect of all antidepressants against placebo was a standardised mean difference of 0.30. None of that says which one fits you.

Which is prescribed more, Celexa or Lexapro?

The page shows federal survey estimates we compute from AHRQ’s Medical Expenditure Panel Survey public-use files for both citalopram and escitalopram: patients and prescriptions in the latest reliable year, and the yearly series from 2014 where AHRQ’s reliability rule allows it, with a direction stated only when the change is larger than the survey’s margin of error. Prescription volume reflects habits, prices, and marketing as much as evidence, so it is context, not a verdict.

Where these numbers come from

Patients and prescriptions: computed by us from AHRQ's public-use Medical Expenditure Panel Survey Prescribed Medicines files, 2014 (HC-168A) to 2024 (HC-254A), with AHRQ's reliability rule (a year with fewer than 60 respondents or a relative standard error over 50% is not shown) — counts of people filling prescriptions, not outcomes. A direction is stated only when the change is larger than the survey's margin of error. Until 29 September 2026 these came from ClinCalc DrugStats, a third-party site; see the correction under each drug where a figure changed.
Medicare/Medicaid: CMS public datasets; commercial insurance publishes no per-drug series, so it renders as an absence, never a synthesized number.
Label facts: the drugs' current FDA labels via DailyMed — quoted in context on each drug's approval-journey page.
FAERS: openFDA — reports, never rates; the caveat travels above every count.
Litigation: court records and regulator documents only, on the linked record pages; settled is never adjudicated.

Explore both drugs in depth: /m/citalopram · /m/escitalopram · or the whole library →